Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
BRIDGEWATER, N.J. - Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company with a market capitalization of $12.87 billion and impressive revenue growth of 20.77% over the last twelve months, today announced successful outcomes from a Phase 2b clinical trial of treprostinil palmitil inhalation powder (TPIP) for treating pulmonary arterial hypertension (PAH). According to InvestingPro data, the company maintains strong liquidity with current assets significantly exceeding short-term obligations. The study met its primary and all secondary efficacy endpoints, demonstrating a significant reduction in pulmonary vascular resistance and improvements in exercise capacity.
The randomized, double-blind, placebo-controlled trial evaluated TPIP’s efficacy and safety, showing a 35% placebo-adjusted reduction in pulmonary vascular resistance and a 35.5-meter improvement in six-minute walk distance. Additionally, a 60% reduction in NT-proBNP concentrations, a biomarker for cardiac stress, was observed. These results were sustained over a 24-hour dosing period, indicating the durability of TPIP’s therapeutic effect.
Insmed plans to initiate Phase 3 trials for TPIP, with studies for pulmonary hypertension associated with interstitial lung disease (PH-ILD) expected to begin before the end of 2025, and for PAH in early 2026. The company will engage with the FDA to inform the design of these trials. InvestingPro analysis shows strong analyst confidence in the company’s future, with 6 analysts recently revising their earnings expectations upward. For deeper insights into Insmed’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
The Phase 2b study involved 102 patients across 44 global sites, with 75% of participants titrating to the highest dose of TPIP. The treatment was generally well-tolerated, with the majority of treatment-emergent adverse events being non-severe. The most common adverse events included cough, headache, and fatigue.
Gene Sullivan, M.D., Chief Product Strategy Officer at Insmed, highlighted the potential of TPIP as a breakthrough in prostanoid therapy for PAH. Martina Flammer, M.D., MBA, Chief Medical Officer, expressed gratitude to patients and clinicians who contributed to the study’s success and is hopeful about TPIP’s future as a preferred prostanoid treatment.
Following the completion of the Phase 2b study, 95% of patients enrolled in a long-term open-label extension to evaluate TPIP at increased doses. Detailed results from the Phase 2b study and the open-label extension are expected to be presented at future medical meetings. The stock currently trades near its 52-week high of $84.91, with InvestingPro analysis indicating the stock is currently overvalued based on its Fair Value model. Subscribers can access over 30 additional financial metrics and insights about Insmed through the platform’s comprehensive analysis tools.
This news is based on a press release statement from Insmed Incorporated.
In other recent news, Insmed Incorporated reported its Q1 2025 earnings, revealing a mixed performance. The company recorded revenue of $92.82 million, surpassing the forecast of $90.78 million, yet posted an earnings per share (EPS) of -$1.42, missing the expected -$1.35. Additionally, Insmed’s shareholders approved an amendment to the 2019 Incentive Plan during their annual meeting, aligning executive compensation with shareholder interests. Analysts at Leerink Partners maintained an Outperform rating for Insmed, expressing optimism about the company’s pipeline, particularly the potential of TPIP and brensocatib. Meanwhile, Jefferies initiated coverage with a Buy rating and set a $105 price target, citing brensocatib’s potential as a blockbuster drug. The company’s commercial asset ARIKAYCE showed significant international growth, notably in Japan and Europe. Insmed’s management continues to emphasize its robust cash position, holding approximately $1.2 billion, to support upcoming product launches and initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.